A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback
The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday announced two share placements to raise a combined HK$2.71 billion ($348 million) in new funds. The company plans to…
Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) saidon Wednesday that its revenue for the first half of 2025 reached 15.76 billion yuan ($2.19 billion), up 15.9% year-on-year. Its…
Recent Articles
Zai Lab under pressure over clinical results and rival drugs
9688.HK
ZLAB.US
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
1276.HK
600276.SHG
RELATED ARTICLES
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK -
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Zai Lab under pressure over clinical results and rival drugs
9688.HK ZLAB.US
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
- RNA drug developer Ribo Life targets fresh funding channel
-
Investors pile into CANbridge stock but can the rally last?
1228.HK
